Hepion Pharmaceuticals, Inc. (CTRVP) Operating income 2016–2025
Hepion Pharmaceuticals, Inc. (CTRVP) annual operating income history from SEC filings — each fiscal year as reported.
-$4.2MFY2025 · since FY2016: -$21.0M → -$4.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$4.2M | +78.5% |
| FY2024 | -$19.3M | +60.1% |
| FY2023 | -$48.4M | -6.5% |
| FY2022 | -$45.5M | -49.6% |
| FY2021 | -$30.4M | -50.9% |
| FY2020 | -$20.1M | -159.3% |
| FY2019 | -$7.8M | +46.8% |
| FY2018 | -$14.6M | +29.3% |
| FY2017 | -$20.6M | +1.8% |
| FY2016 | -$21.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CTRVP financial trends
CTRVP RevenueCTRVP Net incomeCTRVP Net marginCTRVP Gross profitCTRVP Gross marginCTRVP Operating marginCTRVP Operating cash flowCTRVP Free cash flowCTRVP Capital expendituresCTRVP Return on equityCTRVP Stock buybacksCTRVP Dividends paidCTRVP Total assetsCTRVP Total liabilitiesCTRVP Shareholders’ equityCTRVP overview →